Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...
GiveDirectly got $50 gift cards out to SNAP recipients during last month’s shutdown through a new approach to cash assistance ...
Boehringer Ingelheim officials weren't available Monday to say how much of the company's $10 billion investment would be made ...
Boehringer, one of Connecticut’s largest pharmaceutical employers, has reached an agreement with the U.S. government to lower ...
Collaboration aims to accelerate the development of treatments for chronic kidney disease (CKD) and other conditions Rectify ...
Rectify Pharmaceuticals has entered a strategic research and licensing agreement with Boehringer Ingelheim to accelerate the ...
"Trump's painfully slow exit from briefing leaves viewers stunned. Cameras reveal the hidden suffering behind the facade.
Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.
The headquarters for Boehringer Ingelheim in Ridgfield. Photo courtesy of Boehringer Ingelheim RIDGEFIELD – The biopharmaceutical company Boehringer Ingelheim will ...
Nxera Pharma is to regain full rights to its GPR52 agonist program for schizophrenia after Boehringer Ingelheim decided not ...
Boehringer Ingelheim has announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD (nerandomilast) ...
"Watch as Trump's White House briefing takes a surprising turn at the podium, leaving viewers puzzled and intrigued. What ...